News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Patients With Non-Small Cell Lung Carcinoma Most Likely to Benefit From ALK Inhibition Therapy Identified by Novel Test, Seoul National University Hospital Study


12/19/2012 8:01:57 AM

Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients are highly responsive to ALK-specific kinase inhibitors such as crizotinib. However, current diagnostic tests have limitations. Researchers have now developed and tested a promising new method for screening ALK fusions in NSCLC. This new diagnostic assay offers a cost-effective and easy-to-perform alternative to existing tests. The study is published in The Journal of Molecular Diagnostics.

Read at Medical News Today
Read at News Release
Read at Elsevier


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES